Illumina Acquires San Diego Genetic Analysis Startup in $100 Million Deal by Chris Jennewein • Times of San Diego May 15, 2018, 11:15 p.m. May 16, 2018, 7:20 a.m. Share this: ...

Illumina originally spun off Grail in early 2017. Grail plans to launch its test for early detection of cancers, Galleri, next year. Illumina already owns 14.5% of the company, which it started in ...

Illumina, Inc. ILMN recently announced that it collaborated with QIAGEN N.V. QGEN to expand the availability and use of NGS-based In-Vitro Diagnostic (“IVD”) test kits, including companion ...

Biotech firm Illumina will buy back cancer-detection startup Grail in an $8 billion deal that will buy out investors including Amazon chief Jeff Bezos, the companies said Monday. The deal ...

Illumina, Inc., a global leader in DNA sequencing and array-based technologies, announced a series of updates to its NovaSeq X Series, delivering the NovaSeq X single-flow-cell system alongside a ...

Driven by the need for a tool to address African genomic diversity, Illumina was selected to develop an array for genome-wide association studies (GWAS) by the Human Heredity and Health in Africa ...

Illumina, Inc. has announced availability of its new TruSeq Custom Enrichment kits which enable researchers to economically design and target genomic regions of interest ranging from 700 kilobases (Kb ...

The Illumina® Expression BeadChip® arrays are the preferred system for array-based gene expression studies because of their low input requirement, high sensitivity, low cost and high throughput.

SEOUL, South Korea--(BUSINESS WIRE)--On June 23, 2020, Illumina, a global leader in DNA sequencing and array-based technologies, announced it has received regulatory approval from South Korea’s ...

Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced a series of updates to its NovaSeq X Series, delivering the NovaSeq X single-flow ...